2,4-Pyrimidinediamine, N4-cyclopropyl-N2-(3,4-dimethoxyphenyl)-5-(trifluoromethyl)-

A single dose of SBP-7455 (compound 26) (30 mg/kg) is orally administered to mice. The T_max for SBP-7455 is approximately 1 h, the C_max is 990 nM and the T_1/2 is 1.7 h. The plasma concentration of SBP-7455 remains above the ULK1 IC₅₀ for almost 4 h after oral dosing^[1].
The mice are dosed with SBP-7455 (compound 26) (10 mg/kg) by oral gavage, and liver samples were collected after 2 h. The results reveals robust inhibition of pATG13 (Ser318), as well as downregulation of total ATG13 and ULK1 levels by SBP-7455^[1].